在接受PSMA放射性配体疗法和恩杂鲁胺治疗的转移性去势抵抗性前列腺癌患者的¹⁷⁷Lu-PSMA-617扫描中PSMA表达增加：一个潜在的改变游戏规则的因素。
Increased PSMA Expression in 177 Lu-PSMA-617 Scan in Metastatic Castrate-Resistant Prostate Cancer Patient Treated With PSMA Radioligand Therapy and Enzalutamide : A Potential Game-Changer.
作者信息
Aggarwal Piyush, Kaur Komalpreet, Sood Ashwani, Periasamy Kannan, Nagi Shreya, Mittal Bhagwant Rai
机构信息
From the Departments of Nuclear Medicine.
Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Clin Nucl Med. 2023 May 1;48(5):411-413. doi: 10.1097/RLU.0000000000004529. Epub 2023 Jan 12.
Androgen deprivation therapy plays an integral role in the treatment algorithm of advanced prostate cancer. Enzalutamide has shown great benefit in castrate-sensitive as well as resistant prostate cancer. Few studies have shown that enzalutamide can potentially increase the PSMA expression on 68 Ga-PSMA-11 PET/CT imaging in patients with metastatic castrate-resistant prostate cancer. We present an interesting case where addition of short course of enzalutamide resulted in increased localization of 177 Lu-PSMA-617 in metastatic lesions on posttherapy scan pointing to the added benefit of PSMA RLT.
雄激素剥夺疗法在晚期前列腺癌的治疗方案中起着不可或缺的作用。恩杂鲁胺已在去势敏感性前列腺癌以及去势抵抗性前列腺癌中显示出巨大益处。很少有研究表明，恩杂鲁胺可能会增加转移性去势抵抗性前列腺癌患者在68 Ga-PSMA-11 PET/CT成像上的前列腺特异性膜抗原（PSMA）表达。我们报告了一个有趣的病例，短期使用恩杂鲁胺后，治疗后扫描显示转移性病变中177 Lu-PSMA-617的定位增加，这表明前列腺特异性膜抗原放射性配体疗法（PSMA RLT）有额外的益处。
Zotero 插件